TB Alliance Statement on Phase II Trial of Vaccine Candidate MVA85A
The phase 2b clinical trial of the TB vaccine candidate MVA85A is historic, the first efficacy study of a novel […]
The phase 2b clinical trial of the TB vaccine candidate MVA85A is historic, the first efficacy study of a novel […]
Pyrazinamide (PZA) is an incredibly important sterilizing agent in the treatment of tuberculosis and is considered responsible for reducing the
The Global Alliance for TB Drug Development (TB Alliance) is pleased to announce the appointment of Dr. Carlos Morel to
The US FDA approval of bedaquiline is historic, as it marks the first drug in a new class approved to
Tuberculosis (TB) is a major cause of illness and death among children in low- and middle-income countries, but the current
Even though it’s preventable and treatable, tuberculosis (TB) is a top ten killer of children worldwide. Today, the ACTION Partnership
NEW YORK, NY/GENEVA, SWITZERLAND – A new partnership announced today will increase efforts to coordinate the development of complementary novel
“The World Health Organization’s Global Tuberculosis Report 2012 shows that the overall outlook for tuberculosis is improving, albeit slowly. This
As partners of the Critical Path to TB Drug Regimens (CPTR) initiative prepare to gather for their annual meeting, the
PARIS AND NEW YORK, September 20, 2012 – Sanofi (EURONEXT: SAN and NYSE: SNY) and the Global Alliance for TB